Markets
Three Mile Island Nuclear Plant
(Photo by ANDREW CABALLERO-REYNOLDS/AFP via Getty Images)

Nuke stocks jump on Three Mile Island deal

Constellation plans to restart plant on the site of worst-ever US nuclear disaster, which closed for commercial reasons in 2019.

Nuke stocks are up after Constellation Energy announced plans to restart its shuttered Three Mile Island nuclear plant in Pennsylvania — the site of the worst-ever US nuclear power disaster — as part of a 20-year deal to supply carbon-free power to Microsoft’s growing datacenter business.

Rising expectations about the growing demand for energy to needed for artificial intelligence have supercharged utility stocks this year.

The normally sleepy S&P 500 utilities sector, typically considered a defensive area of the stock market to hide out from economic uncertainty, is up roughly 24% in 2024, posting a bigger gain than the tech-heavy Nasdaq 100 index, for example.

On Friday, power providers jumped amid another otherwise soft day for stocks. Constellation had the biggest gain in the S&P 500 in early trading. Vistra Corp., which owns nuclear power assets and has talked up their potential AI linkages, was in second place. Fellow nuclear power providers NRG and Exelon also posted solid gains.

And if you’re looking further upstream, there are huge advances, as well. The Global X Uranium ETF which holds companies that produce the raw materials that facilitate nuclear fission, is soaring, as is the Sprott Junior Uranium Miners ETF. Cameco Corp, the Canada-based uranium miner that’s the largest by market cap, was up more than 9% on Friday morning.

More Markets

See all Markets
markets

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.